AI Engines For more Details: Perplexity Kagi Labs You
Allergic Conjunctivitis: Olopatadine hydrochloride is primarily used to relieve symptoms of allergic conjunctivitis, such as itching, redness, tearing, and swelling of the eyes.
Allergic Rhinitis: It may also be used to treat symptoms of allergic rhinitis (hay fever), such as sneezing, runny or itchy nose, and nasal congestion.
Eye Irritation: Olopatadine hydrochloride can help reduce irritation and discomfort caused by allergens, pollutants, or other environmental factors.
Symptom Relief: By blocking histamine receptors in the eyes and nasal passages, olopatadine hydrochloride can provide relief from symptoms associated with seasonal or perennial allergies.
Prevention of Eye Allergy Symptoms: Some formulations of olopatadine hydrochloride, such as eye drops, are used as a preventive measure to reduce the frequency and severity of allergic conjunctivitis symptoms.
Minimal Systemic Effects: Olopatadine hydrochloride is generally well-tolerated and has minimal systemic absorption when used as directed, which helps reduce the risk of side effects compared to oral antihistamines.
Long-Lasting Relief: Olopatadine hydrochloride eye drops, in particular, are known for providing long-lasting relief from allergic eye symptoms with once- or twice-daily dosing.
Pataday and Pazeo: Pataday (olopatadine hydrochloride 0.2%) and Pazeo (olopatadine hydrochloride 0.7%) are newer formulations of olopatadine that are designed for once-daily dosing and provide extended relief from allergic conjunctivitis symptoms.
Nasal Allergy Relief: While olopatadine hydrochloride is primarily used for eye symptoms, it may also have some benefit in relieving nasal allergy symptoms when used as a nasal spray.
Side Effects: Common side effects of olopatadine hydrochloride may include mild burning or stinging sensation in the eyes upon application, headache, and bitter taste if accidentally ingested.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0 | 0 |
| Allergies | 0.7 | 0.2 | 2.5 |
| Allergy to milk products | 0.1 | 0.1 | |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 0.4 | 0.7 | -0.75 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.1 | 2 |
| Ankylosing spondylitis | 0.3 | 0.1 | 2 |
| Anorexia Nervosa | 0.1 | 0.3 | -2 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 0.6 | 0.2 | 2 |
| Atherosclerosis | 0.1 | 0.7 | -6 |
| Atrial fibrillation | 0.4 | 0.4 | |
| Autism | 0.6 | 0.6 | 0 |
| Autoimmune Disease | 0 | 0.2 | 0 |
| Barrett esophagus cancer | 0 | 0 | |
| Biofilm | 0 | 0 | |
| Bipolar Disorder | 0.1 | 0.3 | -2 |
| Brain Trauma | 0 | 0.3 | 0 |
| Carcinoma | 0.4 | 0.4 | 0 |
| Celiac Disease | 0.5 | 0.4 | 0.25 |
| Cerebral Palsy | 0 | 0.3 | 0 |
| Chronic Fatigue Syndrome | 0.2 | 1 | -4 |
| Chronic Kidney Disease | 0.3 | 0.2 | 0.5 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0.2 | 0 |
| Chronic Urticaria (Hives) | 0 | 0 | |
| Coagulation / Micro clot triggering bacteria | 0 | 0.3 | 0 |
| Cognitive Function | 0.4 | 0.2 | 1 |
| Colorectal Cancer | 0.3 | 0.2 | 0.5 |
| Constipation | 0.1 | 0.2 | -1 |
| Coronary artery disease | 0.1 | 0.2 | -1 |
| COVID-19 | 0.8 | 1.9 | -1.37 |
| Crohn's Disease | 0.6 | 0.6 | 0 |
| cystic fibrosis | 0.2 | -0.2 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Denture Wearers Oral Shifts | 0 | 0 | |
| Depression | 0.6 | 1 | -0.67 |
| Dermatomyositis | 0 | 0 | |
| Eczema | 0 | 0 | 0 |
| Endometriosis | 0.3 | 0.3 | 0 |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 0 | 0 | |
| Fibromyalgia | 0.6 | 0.6 | |
| Functional constipation / chronic idiopathic constipation | 0.5 | 0.3 | 0.67 |
| gallstone disease (gsd) | 0.4 | 0.2 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0 | |
| Generalized anxiety disorder | 0 | 0 | 0 |
| Glioblastoma | 0 | 0 | |
| Gout | 0.1 | 0.1 | |
| Graves' disease | 0.1 | 0.6 | -5 |
| Gulf War Syndrome | 0 | 0 | |
| Halitosis | 0 | 0 | 0 |
| Hashimoto's thyroiditis | 0.6 | 0.6 | |
| Heart Failure | 0.1 | 0.3 | -2 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0 | 0 | |
| High Histamine/low DAO | 0.2 | 0.1 | 1 |
| hyperglycemia | 0 | 0 | |
| hypertension (High Blood Pressure | 0.4 | 0.3 | 0.33 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.1 | 0.2 | -1 |
| Inflammatory Bowel Disease | 0.1 | 0.8 | -7 |
| Insomnia | 0.4 | 0.3 | 0.33 |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 0.6 | 0.3 | 1 |
| ischemic stroke | 0.1 | 0.2 | -1 |
| Liver Cirrhosis | 0.6 | 0.6 | 0 |
| Long COVID | 0.1 | 0.7 | -6 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0.4 | -0.4 | |
| Mast Cell Issues / mastitis | 0 | 0.1 | 0 |
| ME/CFS with IBS | 0 | 0.6 | 0 |
| ME/CFS without IBS | 0 | 0.9 | 0 |
| membranous nephropathy | 0 | 0 | |
| Menopause | 0 | 0.2 | 0 |
| Metabolic Syndrome | 0.6 | 0.6 | 0 |
| Mood Disorders | 0.3 | 0.3 | 0 |
| multiple chemical sensitivity [MCS] | 0 | 0 | |
| Multiple Sclerosis | 0.4 | 0.9 | -1.25 |
| Multiple system atrophy (MSA) | 0.1 | -0.1 | |
| myasthenia gravis | 0 | 0.2 | 0 |
| neuropathic pain | 0.2 | -0.2 | |
| Neuropathy (all types) | 0 | 0.2 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 0.3 | 1.33 |
| Obesity | 1.2 | 0.6 | 1 |
| obsessive-compulsive disorder | 0.1 | 0.3 | -2 |
| Osteoarthritis | 0.1 | 0.1 | 0 |
| Osteoporosis | 0.3 | 0.3 | 0 |
| pancreatic cancer | 0 | 0 | 0 |
| Parkinson's Disease | 0.4 | 1.4 | -2.5 |
| Polycystic ovary syndrome | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.3 | 0 | 0 |
| Primary sclerosing cholangitis | 0 | 0.1 | 0 |
| Psoriasis | 0.7 | 0.2 | 2.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | 0.5 | 1.6 |
| Rosacea | 0.1 | 0.2 | -1 |
| Schizophrenia | 0.1 | 0.3 | -2 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0 | 0.3 | 0 |
| Sleep Apnea | 0.4 | 0.2 | 1 |
| Slow gastric motility / Gastroparesis | 0.1 | 0.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0 | 0 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.2 | 1.5 |
| Systemic Lupus Erythematosus | 0 | 0.5 | 0 |
| Tic Disorder | 0.1 | 0.3 | -2 |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.1 | 0.3 | -2 |
| Type 2 Diabetes | 0.6 | 0.6 | 0 |
| Ulcerative colitis | 0.4 | 0.3 | 0.33 |
| Unhealthy Ageing | 0.3 | 0.2 | 0.5 |
| Vitiligo | 0.1 | 0.1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
